Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    TopAbstracts in Diabetes 10/07/2008 - (DGNews)
    Depression Linked to Higher Death Rates From All Causes Among Elderly With Diabetes - (DGNews)
    TopAbstracts in Diabetes 09/30/2008 - (DGNews)
    Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial - (BMJ)
    Candesartan Increases Regression of Retinopathy in Type 2 Diabetes, Reduces Incidence in Type 1 Diabetes - (DGNews)

    News archive

     Recent webcasts/CME - Diabetes
      Hyperglycemia in Acute Coronary Syndromes
      Impact of Insulin Resistance on Cardiometabolic Risk
      Reducing Cardiovascular Morbidity and Mortality Through RAAS Modulation: New Trial Data
      Clinical Imperatives for Treating Patients with Diabetes
      Cardiometabolic Risk and Risk Management

      Webcasts/CME archive

       Recent cases - Diabetes
        Successful Desensitization with Human Insulin in a Patient with an Insulin Allergy and Hypersensitivity to Protamine: A Case Report
        Diabetic Fetopathy Associated with Bilateral Adrenal Hyperplasia and Ambiguous Genitalia: A Case Report
        Somatostatinoma: A Rare Cause of Diabetic Ketosis
        New Onset Diabetes Complicated by Haemolysis and Rhabdomyolysis: A Case Report and Review of the Literature
        Diabetic Control and Atypical Antipsychotics: A Case Report

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Ranbaxy Gains Tentative Approval to Market Glimepiride Tablets

        PRINCETON, NJ -- July 21, 2005 -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market glimepiride tablets, 1 mg, 2 mg, 4 mg, and 8 mg.

        Total annual market sales for Glimepiride were $336.6 million (+22.4%) (IMS -- MAT: March 2005).

        Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled by diet and exercise alone. Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone do not result in adequate glycemic control. Glimepiride is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic agent. Combined use of Glimepiride and insulin may increase the potential for hypoglycemia.

        "We are pleased to receive this tentative approval for Glimepiride Tablets. This product represents an interesting opportunity for Ranbaxy in which we will offer four strengths of this oral hypoglycemic agent to support patient compliance. Product will be launched following final approval from the FDA on October 6, 2005," according to Jim Meehan, Vice President of Sales and Marketing for RPI.

        Ranbaxy Pharmaceuticals Inc. ("RPI") based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited ("RLL"), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.


        SOURCE: Ranbaxy Pharmaceuticals Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send